Article - Limited access to UNIGE
Other version: http://onlinelibrary.wiley.com/store/10.1111/j.1365-2133.2005.06657.x/asset/j.1365-2133.2005.06657.x.pdf?v=1&t=hkp6zj...
Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model
|Published in||British Journal of Dermatology. 2005, vol. 153, no. 4, p. 758-766|
|Abstract||BACKGROUND: Psoriasis is considered as a chronic immune-mediated disease characterized by inflammation and proliferation of the epidermis. OBJECTIVES: Targeting intercellular adhesion molecule 1 (ICAM-1) is an attractive therapeutic option as this molecule is critically involved in leucocyte adhesion and extravasation as well as in lymphocyte activation. METHODS: We have selected the fully human monoclonal antibody MOR102 (#5) against ICAM-1 from the Human Combinatorial Antibody Library (HuCAL). This antibody, as human IgG4 [corrected] was tested for its ability to interfere with lymphocyte activation and adhesion in vitro as well as for its antipsoriatic efficacy in vivo using the psoriasis-severe combined immunodeficient (SCID) mouse model. RESULTS: The antibody demonstrated efficient inhibition of lymphocyte adhesion to ICAM-1 in vitro, with an IC(50) of approximately 0.4 microg mL(-1) (3 nmol L(-1)). In addition, MOR102 (#5) reduced lymphocyte proliferation in mixed lymphocyte cultures by approximately 50%. The in vivo efficacy of MOR102 (#5) was tested on grafts derived from lesional skin of patients with chronic plaque-stage psoriasis transplanted on to SCID mice. Intraperitoneal injection of 10 mg kg(-1) of MOR102 (#5) antibody every alternate day over a period of 4 weeks resulted in reconstitution of orthokeratotic differentiation and a significant (P < 0.05) reduction in epidermal thickness as well as marked reduction in the inflammatory infiltrate. Therapeutic activity may be related to the targeting of ICAM-1 on keratinocytes and thus preventing efficient activation of local T cells. CONCLUSIONS: Based on the efficacy of the fully human monoclonal antibody MOR102 (#5) shown in vitro as well as in vivo in the psoriasis-SCID mouse model, initiation of clinical studies is indicated.|
|Keywords||Animals — Antibodies, Monoclonal/immunology/*therapeutic use — Cell Adhesion/immunology — Cell Proliferation — Cells, Cultured — Epidermis/pathology — Humans — Intercellular Adhesion Molecule-1/*immunology — Lymphocyte Activation/immunology — Lymphocyte Culture Test, Mixed — Mice — Mice, SCID — Psoriasis/immunology/pathology/*therapy — Skin Transplantation|
|BOEHNCKE, Wolf-Henning et al. Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. In: British Journal of Dermatology, 2005, vol. 153, n° 4, p. 758-766. https://archive-ouverte.unige.ch/unige:29794|